Melchor Madarang, MD
Infectious Disease · The Villages, FLNPI 1013975366
Payments from drug & device makers
Across 84 payments — averaging $55.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$421
- Amgen$416
- AstraZeneca$412
- Lilly USA, LLC$280
- Abbott$254
- Medtronic$232
- plus $3K from 31 others
What the payments were for
- Food & beverage$4,55198%
- Education$1052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 6 | $421 |
| Amgen(2 entities) | 7 | $416 |
| AstraZeneca | 8 | $412 |
| Lilly USA, LLC | 5 | $280 |
| Abbott | 2 | $254 |
| Medtronic | 2 | $232 |
| Shockwave Medical, Inc | 1 | $173 |
| Boston Scientific | 1 | $168 |
| AbbVie(2 entities) | 3 | $168 |
| Edwards Lifesciences | 1 | $154 |
| Xeris Pharmaceuticals, Inc. | 2 | $151 |
| Bayer | 2 | $136 |
| Dexcom, Inc. | 1 | $131 |
| Viiv Healthcare Company | 7 | $129 |
| Boehringer Ingelheim | 1 | $125 |
| Averitas Pharma Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $124 |
| Avinger Inc. | 1 | $124 |
| Kyowa Kirin, Inc. | 1 | $101 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Insmed, Inc. | 6 | $97 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $95 |
| Merck | 1 | $87 |
| Sanofi-aventis U.S. LLC | 1 | $74 |
| Pfizer | 4 | $72 |
| GSK | 4 | $70 |
| Paratek Pharmaceuticals, Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Seqirus USA Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$174
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$173
- WATCHMAN FLX$168
- SAPIEN 3 Ultra RESILIA$154
- DEXCOM G7 GSS (161)$131
- DEXCOM STELO GLUCOSE BIOSENSOR$131
- AZURE XT DR MRI SURESCAN$128
- RYBELSUS$125
- KRYSTEXXA$125
- Wegovy$125
- Mavyret$125
- JARDIANCE$125
- Qutenza$125
- FARXIGA$125
- Repatha$124
- VOQUEZNA$124
- PANTHERIS$124
- BREZTRI$121
- Kerendia$114
- EVENITY$106
How this compares
$4,656 in reported general payments places this provider in the 70th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 11 | $1,558,403 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 58 | $251,311 |
| EliquisApixaban | 173 | $210,017 |
| JanuviaSitagliptin Phosphate | 47 | $55,595 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $49,942 |
| FarxigaDapagliflozin Propanediol | 39 | $48,136 |
| XareltoRivaroxaban | 35 | $44,227 |
| DescovyEmtricitabine/Tenofov Alafenam | 19 | $41,676 |
| JardianceEmpagliflozin | 30 | $35,893 |
| OzempicSemaglutide | 27 | $33,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $28,063 |
| MounjaroTirzepatide | 17 | $25,220 |
| Repatha SureclickEvolocumab | 30 | $18,884 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $14,362 |
| NexletolBempedoic Acid | 14 | $13,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $412 | $1,606,53950 claims |
| PfizerEliquis | $72 | $210,017173 claims |
| MerckJanuvia | $87 | $55,59547 claims |
| Johnson & JohnsonXarelto | $21 | $44,22735 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $70 | $37,76128 claims |
| Boehringer IngelheimJardiance | $125 | $35,89330 claims |
| Novo NordiskOzempic | $421 | $33,22727 claims |
| Lilly USA, LLCMounjaro | $280 | $25,22017 claims |
| Esperion Therapeutics, Inc.Nexletol | $18 | $13,50114 claims |
| AbbVieSynthroid | $168 | $2,44830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 669 infectious disease providers in Florida.
Other infectious disease in The Villages
- Moti RamgopalFort Pierce$13.5M
- Larry BushAtlantis$9.3M
- Olayemi OsiyemiWest Palm Beach$8.8M
- Charlotte-Paige RolleOrlando$6M
- Edwin DejesusOrlando$5.9M
- Dushyantha JayaweeraMiami$5.1M
- Federico HinestrosaOrlando$5.1M
- Godson OguchiOrange City$5M
- Ammara MushtaqGainesville$2.7M
- Efrain GarciaMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.